

Formulary Update

August 2026

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since May 2026. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests and formulary housekeeping exercises. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Amphotericin lozenges	Oropharyngeal anti-infectant	12.3.2	Discontinued
Framycetin eye drops	Antibacterial	11.3.1	Discontinued
Emedastine eye drops	Anti-inflammatory	11.4.2	Discontinued
Ephedrine nasal drops	Topical decongestant	12.2.2	Discontinued
Levobunolol eye drops	Glaucoma	11.6.1	Discontinued
Flurbiprofen eye drops	Anti-inflammatory	11.8.2	Discontinued
Lidocaine eye drops	Local anaesthetic	11.7	Discontinued
Lusutrombopag	Severe low blood platelets	9.1.4	Discontinued
Additions	Indication	Adult Medicines Formulary entry/ rationale	

Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
---	----------------------------------	---	--

Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Betametasone soluble tablets	Brand name removed	12.3.1	Available generically
Budesonide nasal spray	Brand name removed	12.2.1	Available generically
Emtricitabine, tenofovir alafenamide	Brand name removed	5.3.1.5	Available generically
Dexamethasone eye drops	Brand name removed	11.4.1	Available generically
Brinzolamide, brimonidine eye drops	Brand name removed	11.6.6	Available generically
Brinzolamide, timolol	Brand name removed	11.6.6	Available generically
Empagliflozin	Brand name removed	7.5.2	Available generically
Linagliptin	Brand name removed	6.1.2.6	Available generically
Mupirocin nasal ointment	Brand name removed	12.2.3	Available generically